APAC Psoriasis Drugs Market

APAC Psoriasis Drugs Market Size (2024 to 2029)

The size of the Asia Pacific Psoriasis Drugs Market has been calculated at USD 1.29 billion in 2024 and is expected to grow USD 1.91 billion by 2029, registering a CAGR of 8.24% from 2024 to 2029.

Psoriasis is a chronic inflammatory skin condition that affects about 2% of the population. Immunologic, genetic, and environmental variables play a role in psoriasis, while the exact cause is unknown. Topical medicines, systemic therapy, and biologic therapies are part of the current marketed pharmacological landscape for psoriasis. In recent years, additional immunological components have been discovered, and greater knowledge of psoriasis has led to new biological therapies targeting particular immunological factors that cause psoriasis.

Y-O-Y growth in the aging population in APAC, rising number of product launches, growing awareness initiatives, and the increasing number of psoriasis patients are some of the primary drivers driving the APAC psoriasis medications market forward. People are becoming more aware of psoriasis and its therapies, leading to a growing need for effective psoriasis medications. According to the World Health Organization, psoriasis can strike at any age, although according to certain research, psoriasis begins to emerge at the age of 33. However, according to some studies, the disease strikes people before they reach the age of 46.

Despite the expanding improvements in the psoriasis drugs market, the high cost of these drugs is expected to constitute a stumbling block to market expansion. Furthermore, psoriasis drugs may cause side effects such as high blood pressure, liver damage, and kidney damage, which are expected to limit the market's growth over the forecast period.

This research report on the Asia Pacific psoriasis drugs market has been segmented and sub-segmented into the following categories.

APAC Psoriasis Drugs Market Analysis By Drug Type

• Pharmaceuticals
• Biopharmaceuticals

APAC Psoriasis Drugs Market Analysis By Route of Administration

• Topical
• Systemic
  • Oral
  • Intravenous
  • Others

APAC Psoriasis Drugs Market Analysis By Target

• Tumour Necrosis Factor (TNF)
• Phosphodiesterase Type 4 (PDE4)
• Interleukin

APAC Psoriasis Drugs Market Analysis By Country

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Geographically, the Asia-Pacific (APAC) region is estimated to be the fastest-growing region in the global psoriasis drugs market during the forecast period. Factors such as rising skin disease incidence, rising disposable income, which leads to increased spending on skincare goods, including psoriasis pharmaceuticals, strong presence of important market players, improved healthcare infrastructure, and quick launch of new medications in the region, are expected to support the psoriasis drugs market during the forecast period.

Countries such as India, China, and Japan are increasing their spending on research and development operations in both developed and developing countries, which is expected to boost market growth.

KEY MARKET PLAYERS

Companies playing a notable role in the APAC Psoriasis Drugs Market profiled in this report are Johnson & Johnson (USA), Novartis International AG (Switzerland), Pfizer Inc (USA), Merck, and Co. Inc (USA), Celgene Corporation (USA), Janssen Biotech Inc (USA), Stiefel Laboratories Inc (USA), Takeda Pharmaceutical Company Limited (Japan), Amgen (USA), and AbbVie (USA).